Editorials

Can We Call a Model of Care a “Model” If We Cannot Measure Its Performance?
N.K. Gakhal ..........................................................1493

Physical Examination — Still Relevant in Sjögren Syndrome
R.H. Scofield ..........................................................1495

Identifying the Pathogen by Multiplex Polymerase Chain Reaction in Bone and Joint Infections: Challenges and Future
Y. Achermann, A.S. Zinkernagel .............................1497

Rheumatoid Arthritis

Feasibility of Measurement and Adherence to System Performance Measures for RA in 5 Models of Care
C.E. Barber, J.C. Thorne, V. Ahluwalia, et al ..........................1501

Rheumatological Assessment Is Important for Interstitial Lung Disease Diagnosis
Y. Levi, L. Israeli-Shani, M. Kuchuk, G. Epstein Shochet, M. Koslow, D. Shitrit ............................................1509

Flares in RA Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes
K. Bechman, L. Tweehuysen, T. Garrood, et al ........................1515

Ankylosing Spondylitis

Associations Between Cardiorespiratory Fitness and Arterial Stiffness in AS: A Cross-sectional Study

Psoriatic Arthritis

Influence of Disease Manifestations on Health-related Quality of Life in Early PsA
K. Wervers, J.J. Luime, I. Tchetverikov, et al ........................1526

Incidence and Predictive Factors for Orthopedic Surgery in Patients with PsA
T.W. Nystad, Y.S. Husum, O.N. Furnes, B.T. Fevang ....1532

Systemic Lupus Erythematosus

Zoster after Cyclophosphamide for SLE or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis
C. Garnier, D. Ribes, D. Chauveau, et al ..............................1541

Characteristics and Outcomes of Patients with SLE–associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles
C. Yue, J. Su, R. Gao, et al ..............................................1549

Complement Consumption in SLE Leads to Decreased Opsonophagocytosis In Vitro
A. Mitander, Y. Fei, E. Tysberg, et al ..............................1557

Sjögren Syndrome

Tongue Atrophy in SS Patients with Mucosa-associated Lymphoid Tissue Lymphoma: Autoimmune Epithelitis beyond the Epithelial Cells of Salivary Glands?
E. Zampeli, E.M. Kalogiouri, E. Pinner, C.P. Mavragani, H.M. Moutsopoulos ............................................1565

Systemic Sclerosis

Performance of FVC and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in SSc
K. Showalter, A. Hoffmann, G. Rouleau, et al ........................1572

Pediatric Rheumatology

Increased Soluble Cytoplasmic Bcl-2 Protein Serum Levels and Expression and Decreased Fas Expression in Lymphocytes and Monocytes in JDM
B.L. Liphaus, A.E. Sallum, N.E. Aikawa, et al ........................1577

Effect of the Inclusion of the MCP Joints on the Wrist MRI Scoring System in JIA

Contents continued on page xvi
Infectious Arthritis

Multiplex Polymerase Chain Reaction and Microcalorimetry in Synovial Fluid: Can Pathogen-based Detection Assays Improve the Diagnosis of Septic Arthritis?
C. Morgenstern, N. Renz, S. Cabric, C. Perka, A. Trampuz ................................. 1588

Other Arthritides

Identifying and Addressing Barriers to Osteoporosis Treatment Associated with Improved Outcomes: An Observational Cohort Study

Images in Rheumatology

Muscular Hydatidosis Mimicking Lipoma
M. Colazo-Burlato, B. Alvarez-Lario ...................... 1602

Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose PET/CT in Large-vessel Giant Cell Arteritis
R. Ugolini, F. Muratore, C. Salvarani ...................... 1603

Correspondence

Effects of Co-medication with Glucocorticoids in Biologics Trials
M. Boers ........................................... 1605

Reply
C. Charles-Schoeman, E. Bananis .......................... 1605

Letter

Is SAPHO Syndrome Linked to PASH Syndrome and Hidradenitis Suppurativa by Nicastrin Mutation?
A Case Report C. Li, H. Xu, B. Wang ...................... 1605

Correction

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
D. van der Heijde, D.D. Gladman, M. Kishimoto, et al .......................... 1608

Meetings in Rheumatology .............................. xx